2.6
Impact Factor
Q2
ranking
The Journal of Modern Pharmaceutical Sciences focuses on two major questions of importance to pharmaceutical scientists:
(i) What are the physical and biological barriers that limit the access of drugs to their therapeutic targets?
(ii) How can drugs, excipients, traditional formulations, and novel drug delivery systems be designed to minimize the frequency and severity of adverse effects (including the prediction and preclusion of immunogenicity), maximize the therapeutic index, increase global access, and minimize costs?
Answers to these questions have in the past—and will in the future—be derived from research across a wide array of scientific disciplines, including but not limited to:
The Journal of Modern Pharmaceutical Sciences welcomes high-quality, innovative research that addresses these core themes and promotes advancements in pharmaceutical sciences on a global scale.
The University of Kansas, Lawrence, Kansas, United States
The University of Iowa, Iowa City, Iowa, United States
SUNY − University at Buffalo, Buffalo, New York, United States
Center for Pharmaceutical Physics, Milford, New Jersey, United States
University of Colorado System, Denver, Colorado, United States
University of Parma, Torre d’Isola (Pavia), Italy
Pfizer, Inc., Groton, Connecticut, United States
Merck & Co., Inc., West Point, Pennsylvania, United States
University of Cincinnati, Cincinnati, Ohio, United States
University of Frankfurt, Frankfurt, Germany
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
The University of Kansas, Lawrence, Kansas, United States
University of Eastern Finland School of Pharmacy, KUOPIO, Finland
Bristol Myers Squibb, Basking Ridge, New Jersey, United States
De Montfort University School of Pharmacy, Leicester, United Kingdom
University of Toyama, Toyama, Japan
Genentech Inc, South San Francisco, California, United States
University of Santiago de Compostela, Santiago de Compostela, Spain
Bombay College of Pharmacy India, Mumbai, Maharashtra, India
University of Michigan, Ann Arbor, Michigan, United States
University of Colorado System, Aurora, Colorado, United States
KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
Auburn University, Auburn, Alabama, United States
ETH Zurich, Zurich, Switzerland
Uppsala University, Uppsala, Sweden
AstraZeneca UK Limited, Macclesfield, United Kingdom
AUC Sciences, Newark, Delaware, United States
Federal University of Ceara, FORTALEZA, Ceará, Brazil
Baertschi Consulting LLC, Carmel, Indiana, United States
Silver Spring, Maryland, United States
AstraZeneca R&D Gothenburg, Göteborg, Sweden
Wichita State University, Wichita, Kansas, United States
National Institute of Pharmaceutical Education and Research Department of Pharmaceutics, Mohali, Punjab, India
MacroGenics Inc, Rockville, Maryland, United States
Uppsala University, Uppsala, Sweden
The University of Kansas, Lawrence, Kansas, United States
Merck Research Vaccines Division, West Point, Pennsylvania, United States
University of Greenwich, London, United Kingdom
University of Connecticut, Storrs, Connecticut, United States
University of Copenhagen, København, Denmark
Duquesne University, Pittsburgh, Pennsylvania, United States
GSK plc, Brentford, United Kingdom
University of Cape Town, Rondebosch, South Africa
Amgen Inc, Thousand Oaks, California, United States
University of Pavia, Pavia, Italy
University of Milan, Milano, Italy
Jennifer Chadwick Consulting LLC, Burlington, Massachusetts, United States
GSK, Philadelphia, Pennsylvania, United States
University of Connecticut, Storrs, Connecticut, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Pisa, Pisa, Italy
Genentech Inc, South San Francisco, California, United States
Voisin Consulting Life Sciences Cambridge, Cambridge, Massachusetts, United States
University of the Incarnate Word, San Antonio, Texas, United States
University of Bath, Bath, United Kingdom
Butler University, Indianapolis, Indiana, United States
Bristol-Myers Squibb, New Brunswick, New Jersey, United States
St John Fisher University, Rochester, New York, United States
CMP Pharma Inc, Farmville, North Carolina, United States of America
Viela Bio, Gaithersburg, Maryland, United States
U.S. Food and Drug Administration, Silver Spring, Maryland, United States
University of Wisconsin-Madison, Madison, Wisconsin, United States
Teikyo University, Tokyo, Japan
University of Bari, Bari, Italy
Merck & Co Inc, Kenilworth, New Jersey, United States of America
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
Goethe University Frankfurt, Frankfurt am Main, Germany
University of Strathclyde, Glasgow, United Kingdom
David P. Elder Consultancy, Hertford, United Kingdom
MedImmune LLC, Gaithersburg, Maryland, United States
Politecnico di Torino, Torino, Italy
University of Copenhagen, København, Denmark
Università degli Studi di Milano, Milano, Italy
LMU Munich, München, Germany
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Meiji Pharmaceutical University, Kiyose, Japan
Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, United Kingdom
Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
Merck & Co., Inc., Rahway, New Jersey, United States
Respidex LLC, Dennis, Massachusetts, United States of America
Liverpool John Moores University, Liverpool, United Kingdom
Amgen Inc, Thousand Oaks, California, United States
Linköping University, Linköping, Sweden
GSK plc, Brentford, United Kingdom
Merck & Co Inc, Kenilworth, New Jersey, United States of America
Regeneron Pharmaceuticals, Inc., Colts Neck, New York, United States of America
International Solidarity of Scientists, Danbury, Connecticut, United States
Boehringer-Ingelheim, Southbury, Connecticut, United States
Sanofi Genzyme Drug Discovery and Development, Waltham, Massachusetts, United States
RTI International, Research Triangle Park, North Carolina, United States
Okayama University, Okayama, Japan
University of Otago, Dunedin, New Zealand
University of Toyama, Toyama, Japan
Mah Pharma Consulting LLC, Belle Mead, New Jersey, USA
Tokyo University of Pharmacy and Life Science, Tokyo, Japan
Tokushima University, Tokushima, Japan
National Institute of Health Sciences, Kawasaki, Japan
Queensland University of Technology, Brisbane, Queensland, Australia
Chiba University, Chiba, Japan
National Institute of Health Sciences, Tokyo, Japan
Regis University, Denver, Colorado, United States
Queen’s University Belfast, Belfast, United Kingdom
Amgen Inc, Thousand Oaks, California, United States
Perception Neuroscience, New York, New York, United States
University of Cincinnati, Cincinnati, Ohio, United States
Kanazawa, Japan
Just – Evotec Biologics Inc, Seattle, Washington, United States
F. Hoffmann-LaRoche Ltd., Basel, Switzerland
University of Reading, Reading, United Kingdom
University of Greifswald, Greifswald, Germany
Purdue University, West Lafayette, Indiana, United States
Chiba University, Chiba, Japan
Capstone Development Services, LLC, Rosemont, Illinois, United States
Bristol-Myers Squibb, New Brunswick, New Jersey, United States
Teikyo University, Itabashi-Ku, Japan
The University of Kansas, Lawrence, Kansas, United States
Gilead Sciences Inc., Foster City, California, United States
Module 3 Pharmaceutical Consulting, Incline Village, Nevada, United States
Pfizer Global Research and Development Computational Sciences Center of Emphasis, Cambridge, Massachusetts, United States
Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
AstraZeneca Pharmaceuticals LP, South San Francisco, Delaware, United States
Seoul National University College of Medicine Department of Pharmacology, Seoul, Korea, Republic of
North-West University, Potchefstroom, South Africa
University of Iceland Faculty of Pharmaceutical Sciences, Reykjavik, Iceland
University of Bari Aldo Moro, Bari, Bari, Italy
Kitasato University School of Pharmacy, Minato-Ku, Japan
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Consultant, Santa Vittoria in Matenano, Fermo, Italy
Universita degli Studi di Milano, Milano, Italy
International University of Health and Welfare, Otawara, Japan
Maurin Healthcare Consulting LLC, Wilmington, Delaware, United States
Bristol-Myers Squibb Co Research & Development New Brunswick, New Brunswick, New Jersey, United States
University of Milan, Milano, Italy
Coriolis Pharma Research GmbH, Martinsried, Germany
Novartis Pharmaceuticals, Burlingame, California, United States
University of Milan, Milano, Italy
University of Seville, Sevilla, Spain
University of Washington, Seattle, Washington, United States
University of Copenhagen Faculty of Health and Medical Sciences, København, Denmark
Purdue University, West Lafayette, Indiana, United States
Kanazawa University School of Pharmacy, Kanazawa, Japan
Takasaki University of Health and Welfare, Takasaki, Japan
University of Hyderabad, Hyderabad, India
ORIC Pharmaceuticals, Inc., South San Francisco, California, United States
SAGE Therapeutics, Inc., Cambridge, Massachusetts, United States
Amgen Inc, Thousand Oaks, California, United States
University of Parma, Parma, Italy
Monash University, Parkville, Victoria, Australia
Teva Pharmaceutical Industries Ltd, West Chester, Pennsylvania, United States
Keio University, Minato-Ku, Japan
Kinjo Gakuin University, Nagoya, Japan
Pfizer Inc Chesterfield BioTherapeutics Pharmaceutical Science, Chesterfield, Missouri, United States
Kumamoto University, Kumamoto, Japan
Meijo University, Nagoya, Japan
Teikyo University, Tokyo, Japan
University of Shizuoka, Shizuoka, Japan
University of Milan, Milano, Italy
University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
Johnson and Johnson, Zaventem, Belgium
University of Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, United Kingdom
Monash University, Parkville, Victoria, Australia
East Tennessee State University, Johnson City, Tennessee, United States
Amgen Inc, Thousand Oaks, California, United States
Copenhagen University, København, Denmark
KBI Biopharma, Pickens, South Carolina, United States of America
The University of Kansas, Lawrence, Kansas, United States
Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
University of Colorado Boulder, Boulder, Colorado, United States
University of Copenhagen Faculty of Health and Medical Sciences, København, Denmark
University of Delaware, Newark, Delaware, United States
Takeda Oncology, Cambridge, Massachusetts, United States
VenatoRx Pharmaceuticals Inc, Malvern, Pennsylvania, United States
EpiVax, Inc., Providence, Rhode Island, United States
University of Pavia, Pavia, Italy
Bristol-Myers Squibb, Raritan, New Jersey, United States
University of Pavia, Pavia, Italy
University of Michigan, Ann Arbor, Michigan, United States
St John’s University, Queens, New York, United States of America
The University of Kansas, Lawrence, Kansas, United States
Merck and Co Inc, West Point, Pennsylvania, United States
Novartis Pharmaceuticals Australia Pty Ltd, The Rocks, New South Wales, Australia
Shire, Lexington, Massachusetts, United States
Ipsen Biopharm Limited, Wrexham, UK
Campbell University College of Pharmacy and Health Sciences, Buies Creek, North Carolina, United States of America
University at Buffalo, Buffalo, New York, United States
Pliant Therapeutics, San Mateo, California, United States
Merck & Co Inc, Kenilworth, New Jersey, United States of America
University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
Long Island University – Brooklyn Campus, New York, New York, United States
Sinoveda Canada Inc, Edmonton, Alberta, Canada
Purdue University, West Lafayette, Indiana, United States
University of Toyama, Toyama, Japan
Acadia Pharmaceuticals Inc, San Diego, California, United States
UCB Biopharma SRL, Brussels, Belgium
F Hoffmann-La Roche Ltd, Basel, Switzerland
Bristol-Myers Squibb, Moreton, United Kingdom
Keio University, Minato-Ku, Japan
Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Australia
University of Torino, Torino, Italy
Tohoku University, Sendai, Japan
The University of Osaka, Suita, Japan
University of Montpellier, Montpellier, France
The University of Kansas, Lawrence, Kansas, United States
Amgen, Inc., Thousand Oaks, California, United States of America
Pfizer Andover, Andover, Massachusetts, United States
University of Copenhagen, Copenhagen, Denmark
University of Reading, Reading, United Kingdom
LMU Munchen, Munchen, Germany
AffaMed Therapeutics, New York, New York, United States
Virginia Commonwealth University Department of Pharmaceutics, Richmond, Virginia, United States
Biogen Inc, Cambridge, Massachusetts, United States
Kyoto University Graduate School of Pharmaceutical Sciences Faculty of Pharmaceutical Sciences, Kyoto, Japan
Teva Pharmaceutical Industries Ltd, West Chester, Pennsylvania, United States
Hoshi University Graduate School of Pharmaceutical Sciences, Shinagawa-Ku, Japan
Nagoya City University, Nagoya, Japan
University of Cambridge, Cambridge, United Kingdom
University of Milan, Milano, Italy
SUNY Buffalo, Amherst, New York, United States
BeiGene Guangzhou Innovation Technology Co Ltd, Guangzhou, China
Purdue University Department of Industrial and Molecular Pharmaceutics, West Lafayette, Indiana, United States
Eli Lilly and Company, Indianapolis, Indiana, United States
De Montfort University School of Pharmacy, Leicester, United Kingdom
Howard University, Washington, District of Columbia, United States
Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
Queen’s University Belfast, Belfast, United Kingdom
The University of Tennessee Health Science Center, Memphis, Tennessee, United States
in-ADME Research, New York, New York, United States
AbbVie Inc, North Chicago, Illinois, United States
Malmo University, Malmö, Sweden
Merck & Co Inc, Kenilworth, New Jersey, United States
Merck & Co Inc, Kenilworth, New Jersey, United States of America
China Pharmaceutical University, Nanjing, China
Monash Institute of Pharmaceutical Sciences, Parkville, Australia
ATARA BIOTHERAPEUTICS, Thousand Oaks, California, United States
Bristol Myers Squibb Co, Princeton, New Jersey, United States
Gabriele d’Annunzio University of Chieti and Pescara, Chieti, Italy
Ege University, İzmir, Türkiye
Monash University, Clayton, Victoria, Australia
Creighton University, Omaha, Nebraska, United States
Merck & Co Inc, Kenilworth, New Jersey, United States
Kite Pharma Inc, Santa Monica, California, United States
The University of Hong Kong, Hong Kong, Hong Kong
Covar Pharmaceuticals, Mississauga, Ontario, Canada
Amgen Inc, Thousand Oaks, California, United States
Bausch & Lomb Americas Inc, Bridgewater, New Jersey, United States
Amgen Inc, Thousand Oaks, California, United States
The University of Kansas, Lawrence, Kansas, United States
US Food and Drug Administration, Silver Spring, Maryland, United States
Texas A&M University, College Station, Texas, United States
Utah State University, Logan, Utah, United States
University of Buffalo, University at Buffalo, New York, United States
Nutrilite Health Institute, Buena Park, California, United States
Butler University, Indianapolis, Indiana, United States
RCSI Dublin, Dublin, Ireland
Allergan Irvine, Irvine, California, United States
Bristol-Myers Squibb Pharmaceuticals Ltd Pharmaceutical Research Institute, Wirral, United Kingdom
Bristol Myers Squibb Co, Princeton, New Jersey, United States
Kanazawa University, Kanazawa, Japan
AbbVie Inc, North Chicago, Illinois, United States
US Food and Drug Administration, Silver Spring, Maryland, United States
Johnson & Johnson Pharmaceutical Research and Development LLC, Raritan, New Jersey, United States
Gilead Sciences Inc, Foster City, California, United States
University of Copenhagen, København, Denmark
Solid State Concepts, Aachen, Germany
St John’s University, New York, New York, United States
Coriolis Pharma Research GmbH, Martinsried, Germany
University of Southern California, Los Angeles, California, United States
The University of Tokyo, Bunkyo-Ku, Japan
Liquidia Corporation Inc, Morrisville, North Carolina, United States
Coherus BioSciences Inc, Redwood City, California, United States
Merck & Co Inc – Rahway, Rahway, New Jersey, United States
Amgen Inc, Thousand Oaks, California, United States of America
Incilia Therapeutics Pvt Ltd, Hyderabad, India
Amgen Inc, Thousand Oaks, California, United States
Rutgers Ernest Mario School of Pharmacy Department of Pharmaceutics, Piscataway, New Jersey, United States
MedImmune LLC, Gaithersburg, Maryland, United States
HCA Midwest Health, Kansas City, Missouri, United States
Ritsumeikan University, Kyoto, Japan
Nagasaki University, Nagasaki, Japan
The University of Kansas, Lawrence, Kansas, United States
National Institutes of Health, Bethesda, Maryland, United States
FHNW University of Applied Sciences Northwestern Switzerland – Campus Muttenz, Muttenz, Switzerland
Merck & Co Inc, Kenilworth, New Jersey, United States
The University of Kansas, Lawrence, Kansas, United States
University of Eastern Finland School of Pharmacy, KUOPIO, Finland
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Baylor College of Medicine, Houston, Texas, United States
University of Cincinnati, Cincinnati, Ohio, United States
Himed LLC, Old Bethpage, New York, United States
Monash University, Clayton, Victoria, Australia
Genentech Inc, South San Francisco, California, United States
Pfizer Inc, New York, New York, United States
Genentech Inc, South San Francisco, California, United States
Pfizer Global Research and Development Sandwich, Sandwich, United Kingdom
Merck & Co Inc, Kenilworth, New Jersey, United States of America
The University of Iowa, Iowa City, Iowa, United States
PharMolecular, LLC, Bellingham, Washington, United States
Bend Research Inc., Bend, Oregon, United States
Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
Genentech Inc, South San Francisco, California, United States
Allergan Irvine, Irvine, California, United States
Keio University, Minato-Ku, Japan
University of Macau, Taipa, Macau
Monash University, Clayton, Victoria, Australia
Merck Sharp & Dohme UK Ltd, London, United Kingdom
Experic, Cranbury, New Jersey, United States of America
Taro Pharmaceuticals Inc, Brampton, Ontario, Canada
GlaxoSmithKline Australia Pty Ltd Abbotsford Office, Abbotsford, Australia
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
Exelixis Inc, Alameda, California, United States
Seven Star Pharmaceutical Services, Wilmington, Delaware, United States
Bristol Myers Squibb, Seoul, Korea, Republic of
Allergan Irvine, Irvine, California, United States
Baxter Healthcare Corp Round Lake, Round Lake, Illinois, United States
Kumamoto University Hospital, Kumamoto, Japan
Bristol-Myers Squibb, Framingham, Massachusetts, United States
Invetx, Natick, Massachusetts, United States
Department of Chemical Sciences, Tezpur University, Tezpur, India
University of Florida College of Pharmacy, Gainesville, Florida, United States
Bioserv Corporation, San Diego, California, United States
ViiV Healthcare, Brentford, United Kingdom
AbbVie Inc, North Chicago, Illinois, United States
Amgen Inc, Thousand Oaks, California, United States
Bayer AG, Leverkusen, Germany
University of Lille Faculty of Pharmacy, Lille, France
University of Colorado Cancer Center, Aurora, Colorado, United States
UiT The Arctic University of Norway, Tromsø, Norway
Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States
Kyungpook National University, Daegu, Korea, South
Technion Israel Institute of Technology, Haifa, Israel
Shiga University of Medical Science Hospital Pharmacy, Otsu, Japan
Merck & Co Inc, Kenilworth, New Jersey, United States
Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
Grail Inc., Redwood City, California, United States
National and Kapodistrian University of Athens, Athens, Greece
University of Central Florida, Orlando, Florida, United States
Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany
University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
The University of Kansas, Lawrence, Kansas, United States
Allergan Irvine, Irvine, California, United States
Janssen Pharmaceuticals Research and Development Center Shanghai, Shanghai, China
Genentech Inc, South San Francisco, California, United States
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Bristol-Myers Squibb Co Research & Development New Brunswick, New Brunswick, New Jersey, United States
University of Shanghai for Science and Technology, Shanghai, China
Allergan Irvine, Irvine, California, United States
Centers for Disease Control and Prevention, Atlanta, Georgia, United States
Daiichi Sankyo Inc, Basking Ridge, New Jersey, United States
The WhiteOak Group LLC, Washington, District of Columbia, United States
The University of Kansas, Lawrence, United States
Pharmacology
Pharmaceutical Science
Drug Discovery
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Please follow the hyperlink
Submit manuscript
and upload all of your manuscript files following the instructions given on the screen for
Please ensure you provide all relevant editable source files at every submission and revision. Failing to submit a complete set of editable source files will result in your article not being considered for review. For your manuscript text please always submit in common word processing formats such as .docx or LaTeX.
Please ensure to choose one sub-discipline category which is most suitable for your article from the drop-down list in the Editorial Manager.
Note:It is mandatory to suggest two or more reviewers (Name, Affiliation, Field of Expertise and Email id) at the time of submission.
Conflicts may be financial, academic, commercial, political or personal. Financial interests may include employment, research funding (received or pending), stock or share ownership, patents, payment for lectures or travel, consultancies, nonfinancial support, or any fiduciary interest in a company.
Authors must declare all such interests (or their absence) in writing upon submission of a manuscript. This conflict declaration includes conflicts or potential conflicts of all listed authors. If any conflicts are declared, the journal will publish them with the paper. In cases of doubt, the circumstance should be disclosed so that the editors may assess its significance.
The statement shall be written in a separate section before the Acknowledgments.
Authors are expected to provide a short description of the contributions made by each listed author. This too will be published in a separate section after the Conflict of Interest statement.
Manuscripts should be submitted in Word.
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.
Scientific style
Citation
Reference citations in the text should be identified by numbers in square brackets. Some examples:
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text.
The entries in the list should be numbered consecutively.
If available, please always include DOIs as full DOI links in your reference list (e.g. “https://doi.org/abc”).
If you are unsure, please use the full journal title.
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.
Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” when submitting a paper:
Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.
The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.
The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.
Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclosure of interests provides a complete and transparent process and helps readers form their own judgments of potential bias. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate.
Editorial Board Members and Editors are required to declare any competing interests and may be excluded from the peer review process if a competing interest exists. In addition, they should exclude themselves from handling manuscripts in cases where there is a competing interest. This may include – but is not limited to – having previously published with one or more of the authors, and sharing the same institution as one or more of the authors. Where an Editor or Editorial Board Member is on the author list we recommend they declare this in the competing interests section on the submitted manuscript. If they are an author or have any other competing interest regarding a specific manuscript, another Editor or member of the Editorial Board will be assigned to assume responsibility for overseeing peer review. These submissions are subject to the exact same review process as any other manuscript. Editorial Board Members are welcome to submit papers to the journal. These submissions are not given any priority over other manuscripts, and Editorial Board Member status has no bearing on editorial consideration.
Interests that should be considered and disclosed but are not limited to the following:
Funding: Research grants from funding agencies (please give the research funder and the grant number) and/or research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through publication of this manuscript.
Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through publication of this manuscript. This includes multiple affiliations (if applicable).
Financial interests: Stocks or shares in companies (including holdings of spouse and/or children) that may gain or lose financially through publication of this manuscript; consultation fees or other forms of remuneration from organizations that may gain or lose financially; patents or patent applications whose value may be affected by publication of this manuscript.
It is difficult to specify a threshold at which a financial interest becomes significant, any such figure is necessarily arbitrary, so one possible practical guideline is the following: “Any undeclared financial interest that could embarrass the author were it to become publicly known after the work was published.”
Non-financial interests: In addition, authors are requested to disclose interests that go beyond financial interests that could impart bias on the work submitted for publication such as professional interests, personal relationships or personal beliefs (amongst others). Examples include, but are not limited to: position on editorial board, advisory board or board of directors or other type of management relationships; writing and/or consulting for educational purposes; expert witness; mentoring relations; and so forth.
Primary research articles require a disclosure statement. Review articles present an expert synthesis of evidence and may be treated as an authoritative work on a subject. Review articles therefore require a disclosure statement. Other article types such as editorials, book reviews, comments (amongst others) may, dependent on their content, require a disclosure statement. If you are unclear whether your article type requires a disclosure statement, please contact the Editor-in-Chief.
Please note that, in addition to the above requirements, funding information (given that funding is a potential competing interest (as mentioned above)) needs to be disclosed upon submission of the manuscript in the peer review system. This information will automatically be added to the Record of CrossMark, however it is not added to the manuscript itself. Under ‘summary of requirements’ (see below) funding information should be included in the ‘Declarations’ section.
Summary of requirements
The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Funding’ and/or ‘Competing interests’. Other declarations include Ethics approval, Consent, Data, Material and/or Code availability and Authors’ contribution statements.
Please see the various examples of wording below and revise/customize the sample statements according to your own needs.
When all authors have the same (or no) conflicts and/or funding it is sufficient to use one blanket statement.
Examples of statements to be used when funding has been received:
Examples of statements to be used when there is no funding:
Examples of statements to be used when there are interests to declare:
Non-financial interests: Author C is an unpaid member of committee Z.
Non-financial interests: Author A is on the board of directors of Y and receives no compensation as member of the board of directors.
Non-financial interests: none.
Non-financial interests: Author D has served on advisory boards for Company M, Company N and Company O.
Examples of statements to be used when authors have nothing to declare:
Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.
Ethics approval
When reporting a study that involved human participants, their data or biological material, authors should include a statement that confirms that the study was approved (or granted exemption) by the appropriate institutional and/or national research ethics committee (including the name of the ethics committee) and certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that an independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study. If a study was granted exemption from requiring ethics approval, this should also be detailed in the manuscript (including the reasons for the exemption).
Retrospective ethics approval
If a study has not been granted ethics committee approval prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the manuscript for peer review. The decision on whether to proceed to peer review in such cases is at the Editor’s discretion.
Ethics approval for retrospective studies
Although retrospective studies are conducted on already available data or biological material (for which formal consent may not be needed or is difficult to obtain) ethics approval may be required dependent on the law and the national ethical guidelines of a country. Authors should check with their institution to make sure they are complying with the specific requirements of their country.
Ethics approval for case studies
Case reports require ethics approval. Most institutions will have specific policies on this subject. Authors should check with their institution to make sure they are complying with the specific requirements of their institution and seek ethics approval where needed. Authors should be aware to secure informed consent from the individual (or parent or guardian if the participant is a minor or incapable)
Cell lines
If human cells are used, authors must declare in the manuscript: what cell lines were used by describing the source of the cell line, including when and from where it was obtained, whether the cell line has recently been authenticated and by what method. If cells were bought from a life science company the following need to be given in the manuscript: name of company (that provided the cells), cell type, number of cell line, and batch of cells.
It is recommended that authors check the NCBI database for misidentification and contamination of human cell lines. This step will alert authors to possible problems with the cell line and may save considerable time and effort.
Further information is available from the International Cell Line Authentication Committee (ICLAC).
Authors should include a statement that confirms that an institutional or independent ethics committee (including the name of the ethics committee) approved the study and that informed consent was obtained from the donor or next of kin.
Research Resource Identifiers (RRID)
Research Resource Identifiers (RRID) are persistent unique identifiers (effectively similar to a DOI) for research resources. This journal encourages authors to adopt RRIDs when reporting key biological resources (antibodies, cell lines, model organisms and tools) in their manuscripts.
Examples:
Organism: Filip1tm1a(KOMP)Wtsi RRID:MMRRC_055641-UCD
Cell Line: RST307 cell line RRID:CVCL_C321
Antibody: Luciferase antibody DSHB Cat# LUC-3, RRID:AB_2722109
Plasmid: mRuby3 plasmid RRID:Addgene_104005
Software: ImageJ Version 1.2.4 RRID:SCR_003070
Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes”. The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to assess, improve, maintain, promote or modify health, functioning or health conditions” and a health-related outcome is generally defined as a change in the health of a person or population as a result of an intervention.
To ensure the integrity of the reporting of patient-centered trials, authors must register prospective clinical trials (phase II to IV trials) in suitable publicly available repositories. For example www.clinicaltrials.gov or any of the primary registries that participate in the WHO International Clinical Trials Registry Platform.
The trial registration number (TRN) and date of registration should be included as the last line of the manuscript abstract.
For clinical trials that have not been registered prospectively, authors are encouraged to register retrospectively to ensure the complete publication of all results. The trial registration number (TRN), date of registration and the words ‘retrospectively registered’ should be included as the last line of the manuscript abstract.
Standards of reporting
SCI Index advocates complete and transparent reporting of biomedical and biological research and research with biological applications. Authors are recommended to adhere to the minimum reporting guidelines hosted by the EQUATOR Network when preparing their manuscript.
Exact requirements may vary depending on the journal; please refer to the journal’s Instructions for Authors.
Checklists are available for a number of study designs, including:
Randomised trials (CONSORT) and Study protocols (SPIRIT)
Observational studies (STROBE)
Systematic reviews and meta-analyses (PRISMA) and protocols (Prisma-P)
Diagnostic/prognostic studies (STARD) and (TRIPOD)
Case reports (CARE)
Clinical practice guidelines (AGREE) and (RIGHT)
Qualitative research (SRQR) and (COREQ)
Animal pre-clinical studies (ARRIVE)
Quality improvement studies (SQUIRE)
Economic evaluations (CHEERS)
Summary of requirements
The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Ethics approval’.
Please see the various examples of wording below and revise/customize the sample statements according to your own needs.
Examples of statements to be used when ethics approval has been obtained:
Examples of statements to be used for a retrospective study:
Examples of statements to be used when no ethical approval is required/exemption granted:
Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.
All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. This is especially true concerning images of vulnerable people (e.g. minors, patients, refugees, etc) or the use of images in sensitive contexts. In many instances authors will need to secure written consent before including images.
Identifying details (names, dates of birth, identity numbers, biometrical characteristics (such as facial features, fingerprint, writing style, voice pattern, DNA or other distinguishing characteristic) and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scholarly purposes and the participant (or parent/guardian if the participant is a minor or incapable or legal representative) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases. Detailed descriptions of individual participants, whether of their whole bodies or of body sections, may lead to disclosure of their identity. Under certain circumstances consent is not required as long as information is anonymized and the submission does not include images that may identify the person.
Informed consent for publication should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort meaning.
Exceptions where it is not necessary to obtain consent:
Consent and already available data and/or biologic material
Regardless of whether material is collected from living or dead patients, they (family or guardian if the deceased has not made a pre-mortem decision) must have given prior written consent. The aspect of confidentiality as well as any wishes from the deceased should be respected.
Data protection, confidentiality and privacy
When biological material is donated for or data is generated as part of a research project authors should ensure, as part of the informed consent procedure, that the participants are made aware what kind of (personal) data will be processed, how it will be used and for what purpose. In case of data acquired via a biobank/biorepository, it is possible they apply a broad consent which allows research participants to consent to a broad range of uses of their data and samples which is regarded by research ethics committees as specific enough to be considered “informed”. However, authors should always check the specific biobank/biorepository policies or any other type of data provider policies (in case of non-bio research) to be sure that this is the case.
Consent to Participate
For all research involving human subjects, freely-given, informed consent to participate in the study must be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. In the case of articles describing human transplantation studies, authors must include a statement declaring that no organs/tissues were obtained from prisoners and must also name the institution(s)/clinic(s)/department(s) via which organs/tissues were obtained. For manuscripts reporting studies involving vulnerable groups where there is the potential for coercion or where consent may not have been fully informed, extra care will be taken by the editor and may be referred to the SCI Index Research Integrity Group.
Consent to Publish
Individuals may consent to participate in a study, but object to having their data published in a journal article. Authors should make sure to also seek consent from individuals to publish their data prior to submitting their paper to a journal. This is in particular applicable to case studies.
Summary of requirements
The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Consent to participate’ and/or ‘Consent to publish’. Other declarations include Funding, Competing interests, Ethics approval, Consent, Data and/or Code availability and Authors’ contribution statements.
Please see the various examples of wording below and revise/customize the sample statements according to your own needs.
Sample statements for “Consent to participate”:
Informed consent was obtained from all individual participants included in the study.
Informed consent was obtained from legal guardians.
Written informed consent was obtained from the parents.
Verbal informed consent was obtained prior to the interview.
Sample statements for “Consent to publish”:
The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 1a, 1b and 1c.
The participant has consented to the submission of the case report to the journal.
Patients signed informed consent regarding publishing their data and photographs.
Sample statements if identifying information about participants is available in the article:
Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.
Images will be removed from publication if authors have not obtained informed consent or the paper may be removed and replaced with a notice explaining the reason for removal.
Open Choice allows you to publish open access in more than 1850 SCI Index journals, making your research more visible and accessible immediately on publication.
Benefits:
It is easy to find funding to support open access – please see our funding and support pages for more information.
*) Within the first three years of publication.SCI Index hybrid journal OA impact analysis, 2018.
Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal’s How to publish with us guide.
How can you help improve your manuscript for publication?
Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. The experts at sciindex Nature Author Services can help you with manuscript preparation—including English language editing, developmental comments, manuscript formatting, figure preparation, translation, and more.
You can also use our free Grammar Check tool for an evaluation of your work.
Please note that using these tools, or any other service, is not a requirement for publication, nor does it imply or guarantee that editors will accept the article, or even select it for peer review.
您怎么做才有助于改进您的稿件以便顺利发表?
如果在结构精巧的稿件中用精心组织的英语展示您的作品,就能最大限度地让编辑和审稿人理解并公正评估您的作品。许多研究人员发现,获得一些独立支持有助于他们以尽可能美好的方式展示他们的成果。sciindex Nature Author Services 的专家可帮助您准备稿件,具体包括润色英语表述、添加有见地的注释、为稿件排版、设计图表、翻译等。
您还可以使用我们的免费语法检查工具来评估您的作品。
请注意,使用这些工具或任何其他服务不是发表前必须满足的要求,也不暗示或保证相关文章定会被编辑接受(甚至未必会被选送同行评审)。
発表に備えて、論文を改善するにはどうすればよいでしょうか?
内容が適切に組み立てられ、質の高い英語で書かれた論文を投稿すれば、編集者や査読者が論文を理解し、公正に評価するための最善の機会となります。多くの研究者は、個別のサポートを受けることで、研究結果を可能な限り最高の形で発表できると思っています。sciindex Nature Author Servicesのエキスパートが、英文の編集、建設的な提言、論文の書式、図の調整、翻訳など、論文の作成をサポートいたします。
原稿の評価に、無料の文法チェックツールもご利用いただけます。
これらのツールや他のサービスをご利用いただくことは、論文を掲載するための要件ではありません。また、編集者が論文を受理したり、査読に選定したりすることを示唆または保証するものではないことにご注意ください。
게재를 위해 원고를 개선하려면 어떻게 해야 할까요?
여러분의 작품을 체계적인 원고로 발표하는 것은 편집자와 심사자가 여러분의 연구를 이해하고 공정하게 평가할 수 있는 최선의 기회를 제공합니다. 많은 연구자들은 어느 정도 독립적인 지원을 받는 것이 가능한 한 최선의 방법으로 자신의 결과를 발표하는 데 도움이 된다고 합니다. sciindex Nature Author Services 전문가들은 영어 편집, 발전적인 논평, 원고 서식 지정, 그림 준비, 번역 등과 같은 원고 준비를 도와드릴 수 있습니다.
또한 당사의 무료 문법 검사도구를 사용하여 여러분의 연구를 평가할 수 있습니다.
이러한 도구 또는 기타 서비스를 사용하는 것은 게재를 위한 필수 요구사항이 아니며, 편집자가 해당 논문을 수락하거나 피어 리뷰에 해당 논문을 선택한다는 것을 암시하거나 보장하지는 않습니다.
Open access articles in SciIndex journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles.
Articles are published open access under a CC BY licence (Creative Commons Attribution 4.0 International licence). CC BY articles may be shared and adapted for any purpose, including commercially, so long as the authors are credited.
You may also wish to find out about licence variations that are available to meet funder and institutional open access licence requirements.
2 days
Time to first decision
170 days
Review time
223 days
Submission to acceptance
20 days
Acceptance to publication
aims & scope
The Journal of Modern Pharmaceutical Sciences focuses on two major questions of importance to pharmaceutical scientists:
(i) What are the physical and biological barriers that limit the access of drugs to their therapeutic targets?
(ii) How can drugs, excipients, traditional formulations, and novel drug delivery systems be designed to minimize the frequency and severity of adverse effects (including the prediction and preclusion of immunogenicity), maximize the therapeutic index, increase global access, and minimize costs?
Answers to these questions have in the past—and will in the future—be derived from research across a wide array of scientific disciplines, including but not limited to:
Physical pharmacy
Pharmaceutics
Pharmaceutical technology
Drug delivery
Pharmaceutical engineering
Materials science
Nanotechnology
Animal, human, cellular, and molecular biopharmaceutics
Animal and human pharmacokinetics, pharmacodynamics, and pharmacogenomics
Drug metabolism and transport
Biotechnology
Medicinal chemistry, including drug design and prodrug strategies
Biophysical chemistry
Analytical and bioanalytical chemistry
Physical organic, organic, and computational chemistry
Molecular modeling
Immunology
Biochemistry
Cell and molecular biology
The Journal of Modern Pharmaceutical Sciences welcomes high-quality, innovative research that addresses these core themes and promotes advancements in pharmaceutical sciences on a global scale.